lorazepam has been researched along with tiagabine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| al-Tikriti, MS; Baldwin, RM; Bradberry, C; Bremner, JD; During, M; Malison, RT; Seibyl, JP; Sybirska, E; Zea-Ponce, Y; Zoghbi, S | 1 |
| Brouns, R; Van Paesschen, W | 1 |
| Malison, RT; Morgan, PT | 1 |
1 review(s) available for lorazepam and tiagabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for lorazepam and tiagabine
| Article | Year |
|---|---|
Pilot study of lorazepam and tiagabine effects on sleep, motor learning, and impulsivity in cocaine abstinence.
Topics: Adult; Cocaine-Related Disorders; Cognition Disorders; Disruptive, Impulse Control, and Conduct Disorders; Female; GABA Agonists; GABA Modulators; Humans; Learning; Lorazepam; Male; Middle Aged; Nipecotic Acids; Pilot Projects; Polysomnography; Sleep Initiation and Maintenance Disorders; Tiagabine | 2008 |
7 other study(ies) available for lorazepam and tiagabine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
[123I]iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain.
Topics: Adult; Animals; Binding, Competitive; Brain; Dialysis; Female; Flumazenil; gamma-Aminobutyric Acid; Half-Life; Humans; Hypnotics and Sedatives; Iodine Radioisotopes; Lorazepam; Male; Nipecotic Acids; Ovariectomy; Papio; Receptors, GABA-A; Tiagabine; Tomography, Emission-Computed, Single-Photon | 1993 |
Recurrent complex partial status epilepticus associated with tiagabine rechallenge.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilepsy, Temporal Lobe; Gabapentin; gamma-Aminobutyric Acid; Hippocampus; Humans; Lorazepam; Male; Meningoencephalitis; Nipecotic Acids; Status Epilepticus; Tiagabine; Treatment Outcome | 2002 |